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PURPOSE. A 5-bp deletion in ELOVL4, a photoreceptor-specific
gene, has been associated with autosomal dominant (ad) mac-
ular dystrophy phenotypes in five related families, in which
phenotypes range from Stargardt-like macular dystrophy
(STGD3; Mendelian Inheritance in Man 600110) to pattern
dystrophy. This has been the only mutation identified in
ELOVL4 to date, which is associated with macular dystrophy
phenotypes. In the current study, the potential involvement
was investigated of an ELOVL4 gene variation in adSTGD-like
and other macular dystrophy phenotypes segregating in a large
unrelated pedigree from Utah (K4175).
METHODS. The entire open reading frame of the ELOVL4 gene
was analyzed by direct sequencing in a proband from the
K4175 family. The combination of denaturing high-perfor-
mance liquid chromatography (DHPLC) analysis and direct
sequencing of all available family members was used to further
assess segregation of identified ELOVL4 variants in the pedi-
gree.
RESULTS. A complex mutation, two 1-bp deletions separated by
four nucleotides, was detected in all affected members of the
family. The mutation results in a frameshift and the truncation
of the ELOVL4 protein, similar to the effect of the previously
described 5-bp deletion.
CONCLUSIONS. The discovery of a second mutation in the
ELOVL4 gene segregating with macular dystrophy phenotypes
confirms the role of this gene in a subset of dominant macular
dystrophies with a wide range of clinical expressions and
suggests a role for modifying genes and/or environmental fac-
tors in the disease process. (Invest Ophthalmol Vis Sci. 2001;
42:3331–3336)
S targardt macular dystrophies are a collection of early-onset disorders characterized by macular atrophy sur-
rounded by lipofuscin-containing orange-yellow fundus
flecks. Stargardt disease (STGD; Mendelian Inheritance in
Man [MIM] 248200) can be inherited as an autosomal reces-
sive (ar) trait (MIM 248200) or an autosomal dominant (ad)
trait (MIM 600110; 603786). All recessive forms of STGD
have been linked to a locus on 1p32, containing the ABCR
(ABCA4) gene.1 Mutations in ABCR, a photoreceptor-spe-
cific adenosine triphosphate (ATP)-binding cassette (ABC)
transporter, are causal in arSTGD2 and in a number of other
retinal diseases, such as recessive cone–rod dystrophy
(CRD),3 and some forms of autosomal recessive retinitis
pigmentosa (RP19).4,5 Heterozygous carriers of ABCR vari-
ant alleles are more susceptible to age-related macular de-
generation (AMD), a late-onset complex trait.6,7 Rare auto-
somal dominant forms of STGD-like phenotypes have been
mapped to several loci on the human genome, including
those on chromosome 6q14 (STGD3)8 and 4p (STGD4).9
Recently, we cloned and characterized the gene responsible
for STGD-like macular dystrophy (STGD3) on 6q14.10 The
protein, encoded by this photoreceptor-specific gene, elon-
gation factor of very-long-chain fatty acids (ELOVL4), prob-
ably performs an important function in the biosynthesis of
photoreceptor outer segment membrane components. Af-
fected members in all five families segregating the STGD3 or
other macular dystrophy phenotypes harbored the same
presumed founder mutation, 797-801delAACTT.10 This 5-bp
deletion causes a frameshift and premature termination of
the protein, strongly suggesting the pathogenic nature of
this sequence change. Until now, screening of patients with
AMD or additional families with autosomal dominant macu-
lar dystrophy phenotypes has not revealed any other dis-
ease-associated ELOVL4 sequence variants11 to directly sup-
port the previous conclusion. In the current study, we
investigated the potential involvement of ELOVL4 gene vari-
ation in adSTGD-like and other macular dystrophy pheno-
types segregating in a large pedigree from Utah.
MATERIALS AND METHODS
Recruitment of Subjects
A large family with apparent autosomal dominant macular dystrophy
was identified from the clinic population of the Moran Eye Center of
the University of Utah. Complete eye examinations, including best
corrected visual acuity, dilated fundoscopy, and color fundus photog-
raphy were performed, and blood was collected from all available
family members who were able to come to Salt Lake City. Selected
individuals had digital fluorescein angiograms recorded (Imagenet;
Topcon Optical, Tokyo, Japan) system. Family members unable to
come to Salt Lake City had examinations, photography, and blood
collection performed by their local ophthalmologists. All participants
signed institutionally approved consent forms, and recruitment and
research procedures complied with the tenets of the Declaration of
Helsinki.
Mutation Detection by Direct Sequencing
DNA samples from two first-cousin family members (III-1 and III-7)
were analyzed for ELOVL4 variants by direct sequencing. Each exon of
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the ELOVL4 gene was amplified by PCR with previously described
primers,10 and sequencing was performed according to the manufac-
turer’s protocols (Model ABI 377; PE Biosystems, Foster City, CA).
Similarly, all exons of the ABCA4 and peripherin/RDS genes were
directly sequenced with previously published primer pairs.2
Subcloning of ELOVL4 Alleles
The sequence of mutant ELOVL4 alleles was determined directly from
the chromatograms of heterozygous samples. To further demonstrate
the exact sequence of individual ELOVL4 alleles in exon 6 in patient
III-1, the gel-purified PCR product was cloned into pCR2.1-TOPO
vector using a cloning system (Topo TA Cloning; Invitrogen, San
Diego, CA) according to the manufacturer’s protocol. Twelve individ-
ual clones were picked for sequencing, which was performed as
described earlier.
Segregation Analysis by Denaturing High-
Performance Liquid Chromatography
DNA of all available members of the K4175 pedigree was PCR ampli-
fied with specific primers for exon 6 of ELOVL4.10 After the PCR
reaction, heteroduplex DNA formation was achieved by heating the
samples to 95°C for 2 minutes and then lowering the temperature 1°C
per minute until 60°C was reached. Samples were separated on an
HPLC system (Helix; Varian Instruments, Walnut Creek, CA), using the
standard running program supplied by the manufacturer. Samples
were grouped according to the elution profile. In addition, exon 6 was
directly sequenced in every member of the K4175 pedigree, confirm-
ing the grouping and the exact genotype. To assess the frequency of
ELOVL4 mutant alleles in the general population, the same DHPLC
analysis was performed for exon 6 of ELOVL4 on 292 healthy control
individuals and on 513 patients with diagnosed AMD. One DNA sample
from each group was included on every run as a positive control (a
representative of a specific genotype). If a sample deviated from any of
the controls, indicating a different genotype, it was directly sequenced
as described earlier.
Linkage Analysis
DNA was isolated from venous blood as has been described. For
linkage analysis, DNA was amplified under the following conditions:
100 to 200 ng DNA, 1.5 mM Mg PCR buffer, 200 mm dNTPs, 4%
dimethyl sulfoxide (DMSO), 10 pmol primer, (forward primer end-
labeled with g-ATP, using T4 polynucleotide kinase; Molecular Biology
Resources, Milwaukee, WI), and 1 U Taq polymerase (Roche Molecular
Biochemicals, Indianapolis, IN), in a 25-ml reaction at 94°C for 5
minutes; 8 cycles of 94°C for 20 seconds, 64°C for 20 seconds less
1°/cycle, and 72°C for 40 seconds; followed by 23 cycles of 94°C for
20 seconds, 56°C for 20 seconds, 72°C for 40 seconds, and a final
extension of 72°C for 10 minutes. The resultant PCR products were
electrophoresed on 7% polyacrylamide gels for 3.5 hours. The poly-
morphic marker D6S460 was genotyped in all 25 (12 affected and 13
unaffected) individuals, and two-point linkage analysis was performed
with the LINKAGE program (provided in the public domain by the
Human Genome Mapping Project Resources Center, Cambridge UK,
and available at http://www.hgmp.mrc.ac.uk) under assumptions of a
dominant model, a penetrance of 0.7, and a disease gene frequency of
0.001. Primer sequence and heterozygosity for this marker can be
obtained at http://gdbwww.gdb.org/gdb/gdbtop.html.
FIGURE 1. K4175 pedigree and segregation of genotypes. (A) Filled circles and squares: affected females and males, respectively; stippled circles
and squares: nonpenetrant females and males, respectively; open circles and squares: unaffected females and males, respectively. Below each
individual are genotypes as determined by the dinucleotide marker D6S460 and the combination of DHPLC and direct-sequencing information from
the ELOVL4 locus for the two, single-nucleotide deletions (ELOVL4del) or wild type (1) and the methionine (M) to valine (V) polymorphism
(M299V) in exon 6 of ELOVL4. The disease chromosome is boxed. Affected status of deceased individuals was determined by reports from living
family members. (B) DHPLC profiles for the four possible combinations of ELOVL4 alleles in exon 6. The homozygous 1/1; V/V genotype in
individual III-2 is indistinguishable from the wild-type 1/1; M/M by DHPLC and so was determined by direct sequencing.
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RESULTS
Phenotypic Evaluation of Patients
We identified a large Utah kindred from the clinic population
of the Moran Eye Center with autosomal dominant macular
dystrophy (Fig. 1). In this family, phenotypes ranged from
STGD3 to butterfly-pattern dystrophy12 to bull’s-eye maculopa-
thy (Fig. 2). Twenty-five family members from 10 to 68 years of
age were examined ophthalmoscopically, and blood samples
were obtained for genetic analyses. Twelve family members
exhibited varying degrees of maculopathy with impaired visual
acuity (Table 1). The remaining 13 had completely normal
results in fundus examinations and no evidence of significant
visual loss. The most common age of onset of symptoms was in
the second decade of life, although it varied widely, from as
early as 6 years of age (IV-7), to as late as 63 (individual II-8).
The disease in the latter patient had initially been diagnosed by
her local ophthalmologist as AMD, but the diagnosis was later
changed because of the obvious presence of typical Stargardt-
like flecks rather than AMD-associated soft and hard drusen.
Patients reported blurred central vision, but no nyctalopia, loss
of visual field, or photophobia. Five patients were considered
legally blind (vision 20/200 or worse, bilaterally). At the same
time, several other affected members of the family were still
able to drive and perform job functions.
Deleterious Mutation in the ELOVL4 Gene
The combination of DHPLC analysis and direct sequencing of
all family members revealed a rare, complex mutation in all
those affected (Fig. 1). The mutation can be described as a
deletion of two nucleotides, four nucleotides apart, in exon 6
of the ELOVL4 gene (Fig. 3). It was interesting that this muta-
tion occurred in the same location as the previously described
5-bp deletion and had exactly the same truncating effect on the
ELOVL4 protein: deletion of the last 51 amino acids, including
the dilysine-targeting signal (Fig. 3). Occurrence of the muta-
tion in all affected members of the family and the premature
termination of the protein allow us to suggest the causal role of
this mutation. Additional proof for this statement was gained
from the large-scale analysis of healthy control individuals and
patients with AMD. Not one of 292 general-population control
subjects or 513 patients with AMD (a total of 1610 chromo-
somes) harbored any deleterious changes in exon 6 of ELOVL4.
In addition to the double deletion, the only other detected
variant in the ELOVL4 gene sequences in this family was the
973A 3 G (M299V) change in exon 6. This allele has been
detected as the most frequent single nucleotide polymorphism
(SNP) in the ELOVL4 gene (allele frequency, ;0.1) in the
general population and deemed not to be associated with any
disease phenotype.10,11 We did not find any evidence of seg-
regation of this variant with the disease phenotype (or its
variation) in this study (Fig. 1).
Linkage Analysis
The mutation segregated in an autosomal dominant pattern
with maculopathy in kindred 4175 (Fig. 1). To further confirm
that the dominant disease locus in this kindred resides at the
chromosome 6q14 location of the ELOVL4 gene, we geno-
typed all family members with a highly informative microsat-
ellite marker (D6S460) tightly linked to the ELOVL4 locus. The
marker D6S460 resides less than 0.6 centimorgans (cM) prox-
imal to the ELOVL4 locus and is the marker that has been
completely linked to the disease gene in initial linkage stud-
ies8,13 and is the proximal flanking marker published by Zhang
et al.10 In kindred 4175 a maximum two-point lod score of 3.86
was obtained with genotypes generated by this microsatellite
marker at a recombination fraction of u 5 0.001, providing
additional, significant evidence of localization of the disease
gene locus to the ELOVL4 locus on chromosome 6q14.
Penetrance of the ELOVL4 Mutation
All affected members in kindred 4175 as well as three nonpen-
etrant individuals—III-3, III-8, and IV-12—carried the disease
haplotype of allele 5 for the marker D6S460 and the two
single-nucleotide deletions in the ELOVL4 gene (Fig. 1). One of
the three nonpenetrant individuals was a 10-year-old (IV-12),
well below the average age of onset of symptoms in this family.
However, his father (III-8) and one of the father’s cousins (III-3)
were both 47 years old, carried the deletions, and had com-
pletely normal findings in eye examinations (including normal
fluorescein angiography for individual III-8; Fig. 2C). Yet both
of these individuals have affected siblings, and III-8 has two
affected children (Fig. 1). So far, we have been unable to
identify any environmental or hereditary factors that deter-
mined the nonpenetrant status of these two adults. One of the
many clinical manifestations of maculopathy segregating in the
family could still develop in these individuals at a later age. A
precedent for this in this family is the individual II-8, in whom
the very late onset (at more than 60 years of age) caused an
initial misdiagnosis (as AMD).
DISCUSSION
The macular phenotype of the family described in this study
was diverse and generally consistent with the clinical descrip-
tion of affected members of families with macular dystrophies
linked to 6q14, most of whom are known to harbor the 5-bp
FIGURE 2. Early-phase fluorescein angiograms from representative in-
dividuals in kindred 4175 carrying ELOVL4 deletions. (A) Foveal atro-
phy with extensive flecks (III-1); (B) butterfly-pattern dystrophy of the
central macula without flecks (III-7); (C) normal fluorescein angiogram
(III-8); (D) beaten-metal–appearing macular lesion without flecks (IV-
3); and (E) subtle bull’s-eye hyperfluorescence around the fovea with-
out flecks (IV-10). The absence of a dark choroid was noted in all
individuals.
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deletion in the ELOVL4 gene.10,14 The first two descriptions of
families in which maculopathy was ultimately linked to the
STGD3 locus on 6q14 emphasized the phenotypic similarity to
STGD and fundus flavimaculatus, as evidenced by the presence
of macular atrophic lesions and abundant midperipheral sub-
retinal flecks.8,14 Subsequent studies demonstrated that many
other forms of maculopathy coexist in these STGD3 kindreds.
Lagali et al.15 described a family with a variety of macular
pathologies ranging from macular atrophy with flecks, to pat-
tern dystrophy, to retinal pigment epithelium (RPE) defects in
a ring-shaped pattern.15 Likewise, Griesinger et al.16 reported
that many of the affected family members in their study had

















II 2 74 No No NA NA Normal
II 7 70 No No 20/25 20/25 Normal
II 8 68 63 Yes No 20/400 20/400 Mild foveal pigment disruption with flecks.
III 1 51 8 Yes No 20/200 20/200 Foveal atrophy with flecks
III 2 48 No Yes* 20/20 20/25 Normal
III 3 47 Yes No NA NA Normal
III 4 44 No No NA NA Normal
III 5 50 13 Yes No 20/70 20/50 “Butterfly” pattern dystrophy, no flecks
III 6 51 No No 20/20 20/20 Normal
III 7 49 18 Yes No 20/60 20/50 “Butterfly” pattern dystrophy, no flecks
III 8 47 Yes No 20/20 20/15 Normal
III 9 43 No Yes 20/15 20/15 Normal
III 11 33 27 Yes No 20/80 20/80 Foveal pigment disruption with flecks
IV 1 27 No Yes 20/15 20/20 Normal
IV 2 25 No Yes 20/15 20/15 Normal
IV 3 23 13 Yes Yes 20/80 20/70 “Beaten metal” macula, no flecks
IV 4 21 12 Yes Yes 20/200 20/200 “Beaten metal” macula with flecks
IV 5 27 12 Yes No 20/200 20/200 Foveal pigment disruption with flecks
IV 6 25 7 Yes No 20/200 20/200 Foveal atrophy with flecks
IV 7 22 6 Yes No 20/70 20/80 “Butterfly” pattern dystrophy, no flecks
IV 8 18 No No 20/20 20/15 Normal
IV 9 21 16 Yes No 20/100 20/100 Foveal pigment disruption, no flecks
IV 10 18 18 Yes No 20/40 20/20 “Bulls-eye” fovea, no flecks
IV 11 16 No No 20/20 20/20 Normal
IV 12 10 Yes Yes 20/25 20/25 Normal
NA, documented visual acuity not available.
*Homozygous individual.
FIGURE 3. Complex deletion in the
ELOVL4 gene in patients from the
K4175 pedigree. Partial sequence of
exon 6 in patient III-1. After the ini-
tial sequence analysis determined the
double deletion in exon 6
(ELOVL4het), the PCR product was
cloned and alleles sequenced sepa-
rately. The nucleotide sequences and
protein translations are shown above
and below the direct-sequencing
traces. The double deletion causes a
frameshift that results in a premature
stop codon after 10 amino acids (bot-
tom trace). ELOVL4wt, wild type al-
lele; ELOVL4del (790DT1794DT), al-
lele with the double deletion.
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either central macular atrophy surrounded by flecks or ring-
shaped RPE defects best seen with fluorescein angiography. A
10-generation STGD3-affected family described by Edwards et
al.13 includes one of the families reported to have the 5-bp
deletion in ELOVL4.10 In this very large family, affected mem-
bers commonly had atrophic macular lesions, often with a
“beaten-metal” appearance. Most individuals had extensive
subretinal flecks in the midperipheral retina except in the early
stages of the disorder. A few affected family members showed
a pattern-dystrophy–like appearance or geographic atrophy of
the posterior pole.
It should be noted that not one affected member of all these
families ever exhibited a dark choroid on fluorescein angio-
grams—a feature often considered characteristic of arSTGD.12
The choroidal silence of arSTGD is thought to be due to
blocking of choroidal fluorescence by excessive deposition of
lipofuscin in the RPE secondary to dysfunctional retinoid pro-
cessing by ABCR.12 The general absence of a dark choroid in
ELOVL4-mediated autosomal dominant macular dystrophy im-
plies that excessive lipofuscin deposition is not involved in this
particular disease’s pathogenesis, even though it shares many
clinical similarities with arSTGD.
Some of the Utah family members exhibited macular
changes indistinguishable from STGD (or fundus flavimacula-
tus), such as foveal atrophy or beaten-metal changes sur-
rounded by deep flecks (Fig. 2A). Others had similar atrophic
findings with no flecks (Fig. 2D). Three patients had deep
yellowish lesions in the macula, characteristic of butterfly-
pattern dystrophy (Fig. 2B). Still others (Fig. 2E) had mild to
moderate pigmentary disruption of the fovea, sometimes in a
bull’s-eye pattern. None of the affected members had any
abnormalities of the peripheral retina. Six affected family mem-
bers (III-1, III-7, III-8, IV-3, IV-9, and IV-10) had fluorescein
angiograms performed, but a dark choroid was never seen. The
presence of flecks was strongly associated with poor visual
acuity; only one person with flecks (III-11) had acuity better
than 20/200. Conversely, only one person without flecks (IV-9)
had acuity worse than 20/80.
The nature of the mutation found in the K4175 family is of
specific interest. Similar mutations, involving noncontiguous
deletions on the same allele, are extremely rare and have been
described in only a few instances. For example, the Human
Gene Mutation Database (Institute of Medical Genetics, Cardiff,
UK; available at http://archive.uwcm.ac.uk/uwcm/mg/hgmd0.
html) documents only a handful of mutations of similar nature.
No like mutation, two 1-bp deletions close to each other, has
been described in the literature. Single examples of mutations
in three genes, ATM, FBN1, and HR, in which two deletions
occur in proximity (5–15 bp) on the same allele, have been
described.17–19 In those cases, the deletions always included
more than one nucleotide each (ranging from 2 to 21 bp). A
similar variant in the AVPR2 gene, in which two insertions of
single nucleotides (93insT and 96insT) introduce a stop codon,
has been described.20
In addition to environmental factors, the effect of potential
modifier genes (genotype) on the phenotypic variation should
be seriously considered. An obvious candidate for a modifier is
the ABCR gene, for three reasons: Independent mutations in
ABCR and ELOVL4 result in a similar (STGD) phenotype; ABCR
function is directly dependent on the membrane lipid environ-
ment,21 which, we hypothesize, is determined in part by
ELOVL4 function; and, as we have previously shown, a 6q14-
linked patient with adSTGD who is a heterozygous carrier of a
variant ABCR allele exhibits more severe phenotype than his
siblings.22 Direct sequencing of the entire ABCR and periph-
erin/RDS genes in patients from the K4175 pedigree failed to
uncover any obvious disease-associated variants. To definitively
confirm (or reject) this hypothesis, we are screening several
individuals from all other families in which the autosomal
dominant macular dystrophy phenotype is caused by the
ELOVL4 mutation on the ABCR350 microarray, a recently es-
tablished comprehensive screening tool containing all cur-
rently known (.350) ABCR alleles.23 In general, there was no
definite segregation of the various disease phenotypes within
the K4175 family. For example, one individual diagnosed with
butterfly-pattern dystrophy (III-7) had three affected children,
one with similar pattern dystrophy and two with typical Star-
gardt macular changes. An affected parent with flecks could
have an affected child without flecks, and an affected parent
without flecks could have a child with flecks.
In summary, we have determined a new mutation in the
ELOVL4 gene, which segregates with an autosomal dominant
macular dystrophy phenotype in a large independent pedigree.
This finding not only confirms that mutations in ELOVL4 are
the cause of variable macular phenotypes, but also further
illustrates the complexity of phenotypic expressions of the
genetic variation in photoreceptor-specific membrane-associ-
ated proteins. Together with ABCR, the ELOVL4 gene expands
our knowledge of possible metabolic (and/or signaling) path-
ways in photoreceptor outer segment membranes.
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